Cardioverter-defibrillator does not improve short-term survival among patients with non-ischemic cardiomyopathy and reduced left ventricular ejection fraction.
Clemens JilekThorsten LewalterMatthias PauschingerWolfgang von ScheidtLutz FrankensteinOtmar PfisterRainer HambrechtOliver BruderJohannes BrachmannAndreas HartmannRuth StrasserMatthias HochadelJochen SengesPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2019)
In a real-world setting, no benefit was evident for patients with non-ischemic cardiomyopathy and reduced left ventricular ejection fraction by adding ICD therapy in a short-term follow-up of 12 months in contrast to patients with ischemic cardiomyopathy.
Keyphrases
- ejection fraction
- aortic stenosis
- left ventricular
- heart failure
- cardiac resynchronization therapy
- ischemia reperfusion injury
- cerebral ischemia
- magnetic resonance
- acute myocardial infarction
- mitral valve
- aortic valve
- coronary artery disease
- magnetic resonance imaging
- stem cells
- mesenchymal stem cells
- computed tomography
- acute coronary syndrome
- free survival
- subarachnoid hemorrhage
- percutaneous coronary intervention
- brain injury
- smoking cessation